MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$153,750K
Proceeds from issuance of
common stock,...
$79,999K
Proceeds from common
stock issuances under...
$270K
Proceeds from exercise of
stock options
$59K
Net cash provided by
financing activities
$216,795K
Canceled cashflow
$17,283K
Net change in cash,
cash equivalents and...
$27,982K
Canceled cashflow
$188,813K
Third-party commissions and
offering costs incurred...
$9,833K
Payment of financing and
stock issuance costs
$6,917K
Payments on finance
leases
$533K
Stock based
compensation expense
$12,132K
Reduction in the carrying
amount of rou assets,...
$1,491K
Reduction in the carrying
amount of rou assets,...
$320K
Depreciation and
amortization expense
$268K
Amortization of premium
(accretion of discount) on...
-$111K
Proceeds from sales or
maturities of investments
$105,527K
Net cash used in
operating activities
-$98,561K
Net cash used in
investing activities
-$90,252K
Canceled cashflow
$14,322K
Canceled cashflow
$105,527K
Net loss
-$99,961K
Purchases of investments
$195,382K
Accrued expenses and
other current...
-$4,445K
Non-cash gain on
long-term investment
$3,390K
Prepaid expenses and
other current assets
$2,004K
Accounts payable
-$1,561K
Lease liabilities,
operating
-$1,496K
Net realized gain on
investments in u.s. treasury...
$17K
Lease liabilities,
finance
-$9K
Purchase of property and
equipment
$397K
Back
Back
Cash Flow
source: myfinsight.com
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)